Please Wait...

Aβ 1-40 // Beta Amyloid 1-40

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Amyloid β1-40 is one of the fragments generated after cleavage of the amyloid peptide precursor protein by β and γ secretases. This fragment is also among the most abundant variant of amyloid β peptide found in the cerebrospinal fluid (Portelius et al., 2006; Vigo-Pelfrey et al., 1993). In association with the Aβ1-42 measurement, Aβ1-40 allow normalization of high Amyloid producers in the diagnosis and follow-up of Alzheimer’s Disease (Dorey et al., 2015; Dumurgier et al., 2015).

Bioclinica Lab employs a manual sandwich ELISA for the measurement of Aβ1-40 in human cerebrospinal fluid.


Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

We're hiring recent tech grads in #RTP for #pharma sector! Our innov. clinical financial solution gives our client…
bioclinica (3 hours ago)
Great to be @DrugInfoAssn DIA China! Ask us @bioclinica how sponsors & CROs can optimize electronic data capture…
bioclinica (9 hours ago)
RT @bioclinica: Kinks in the clinical supply chain? Check out how one of our clients is using clinical supply optimization technology for m…
bioclinica (9 hours ago)
RT @bioclinica: Welcoming everyone to KOP for #OCTEast Coast!!
bioclinica (9 hours ago)
Welcoming everyone to KOP for #OCTEast Coast!!
bioclinica (Yesterday)
Case processing is an important aspect of post-marketing drug safety surveillance. Here's a case study showing how…
bioclinica (2 days ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen